Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649981 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CTSLCTSBCTSKSGMS2 | |
| SCHEMBL2701945 | 0.85 | CTSL (0.53) | CTSLCTSBCTSKNAAATSHR | |
| Hydrochloric Acid SCHEMBL30384626 | 0.84 | CTSL (0.51) | CTSLCTSBCTSKNAAATSHR | |
| SCHEMBL4677170 | 0.84 | TSHR (0.54) | CTSLCTSBCTSKNAAATSHR | |
| SCHEMBL17019782 | 0.83 | TSHR (0.58) | CTSLCTSBCTSKNAAATSHR | |
| SCHEMBL1928095 | 0.83 | TSHR (0.58) | CTSLCTSBCTSKNAAATSHR | |
| SCHEMBL6649338 | 0.80 | TSHR (0.54) | CTSLCTSBCTSKNAAATSHR | |
| SCHEMBL2647771 | 0.78 | CARM1 (0.47) | ALDH1A1 | |
| SCHEMBL2647944 | 0.78 | EPHX2 (0.48) | ALDH1A1CTSLCTSBCTSKSGMS2 | |
| SCHEMBL2648383 | 0.78 | CARM1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| CN-101258137-A | Dicycloalkyl urea glucokinase activators | NOVO NORDISK AS (DK) | 2008-09-03 | — | — | CN | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | ALDH1A1 3782/4885CTSL 394/4885CTSB 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.